Condition: Age-Related Macular Degeneration · Sponsor: Astellas Institute for Regenerative Medicine
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD. Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD. This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be tak…
This description comes directly from the study's public registry record.
Astellas Institute for Regenerative Medicine · 800-888-7704 · astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| Retinal Consultants of Arizona LTD, Retinal Research Institute | Phoenix, Arizona, United States | Withdrawn |
| Jules Stein Eye Institute | Los Angeles, California, United States | Recruiting |
| Stanford University Byers Eye Institute | Palo Alto, California, United States | Recruiting |
| Kaiser Permanente Riverside Medical Center | Riverside, California, United States | Recruiting |
| Retina Consultants of Southwest Florida & National Ophthalmic Research Institute | Fort Myers, Florida, United States | Withdrawn |
| Retina Specialty Institute | Pensacola, Florida, United States | Recruiting |
| Emory University Eye Center | Atlanta, Georgia, United States | Recruiting |
| University Retina and Macula Associates | Oak Forest, Illinois, United States | Recruiting |
| Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office | Boston, Massachusetts, United States | Withdrawn |
| Ophthalmic Consultants of Boston | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Kellog Eye Center | Ann Arbor, Michigan, United States | Recruiting |
| Deep Blue Retina | Southaven, Mississippi, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03178149